NPCE
NeuroPace, Inc.
NPCE lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
NPCE Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Unavailable |
NPCE's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
NPCE PE Valuation
NPCE has no meaningful PE right now: it lost money over the past year.
NPCE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect NPCE's losses to shrink, with revenue growing.
NPCE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.56 | +$0.18 |
| Q2 2026 | -$0.57 | +$0.25 |
| Q1 2026 | -$0.65 | +$0.17 |
| Q4 2025 | -$0.66 | +$0.27 |
| Q3 2025 | -$0.74 | +$0.25 |
| Q2 2025 | -$0.82 | +$0.26 |
| Q1 2025 | -$0.82 | +$0.36 |
| Q4 2024 | -$0.93 | +$0.34 |
NPCE is still losing money, but far less than before: $0.56 per share over the past year, against $1.91 at its worst in late 2022.
NPCE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $23.1M | -16% |
| Q2 2026 | $22.8M | -3% |
| Q1 2026 | $22.1M | -2% |
| Q4 2025 | $26.6M | +24% |
| Q3 2025 | $27.4M | +30% |
| Q2 2025 | $23.5M | +22% |
| Q1 2025 | $22.5M | +24% |
| Q4 2024 | $21.5M | +19% |
NPCE's revenue fell from its 2025 peak and has held roughly level since: $23M last quarter, down 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -9% | +0.5 points |
| Q2 2026 | -23% | +6.5 points |
| Q1 2026 | -25% | -2.4 points |
| Q4 2025 | -6.7% | +10 points |
| Q3 2025 | -9.5% | +11 points |
| Q2 2025 | -29% | +3.3 points |
| Q1 2025 | -23% | +19 points |
| Q4 2024 | -17% | +11 points |
NPCE's operating margin was −9% last quarter, up 0.5 points from the same quarter a year ago, near the top of its range since 2020.
NPCE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.8M | -$805K |
| Q2 2026 | -$4M | -$1.8M |
| Q1 2026 | -$6M | +$1.5M |
| Q4 2025 | $409K | +$5.2M |
| Q3 2025 | -$2M | -$150K |
| Q2 2025 | -$2.3M | +$1.7M |
| Q1 2025 | -$7.5M | +$113K |
| Q4 2024 | -$4.8M | -$1.5M |
NPCE has burned cash in almost every quarter: −$12M over the past year, against −$17M the year before.
NPCE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +242K shares |
| 1 year | +3.7% | +1.2M shares |
| 3 years | +32% | +8.3M shares |
| 5 years | +96% | +16.8M shares |
NPCE has 34M diluted shares, up 3.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $49.5M |
| Q4 2020 | — |
NPCE hasn't bought back shares in the past year.
NPCE Net Leverage
NPCE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NPCE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.0 | Neutral |
| Stochastic | 7.3 | Oversold |
NPCE's weekly RSI is 39 (neutral) and its Stochastic is 7 (oversold).
NPCE PE vs Healthcare Sector
NPCE has no meaningful PE right now: it lost money over the past year.
NPCE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.7 | 5.2% below |
| 20 week MA | $14.0 | 14% below |
| 50 week MA | $15.0 | 20% below |
| 100 week MA | $13.3 | 9.4% below |
| 200 week MA | $10.6 | 14% above |
NPCE has fallen below most of its moving averages, though it's still 14% above its 200-week average.
NPCE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $25.4 | $9.73 | -62% |
| 2022 | $9.73 | $1.36 | -86% |
| 2023 | $1.36 | $10.3 | +658% |
| 2024 | $10.3 | $10.7 | +3.5% |
| 2025 | $10.7 | $16.0 | +50% |
| 2026 YTD | $16.0 | $12.0 | -25% |
NPCE's yearly returns have swung widely, from +658% in 2023 to −86% in 2022. It's down 25% so far in 2026.